SCHEMBL3048539

SCHEMBL3048539

O=C1NCc2c(Cl)ccc(I)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.43
CLK2 P49760 1/20 0.43
CLK3 P49761 1/20 0.43
MAP3K9 P80192 2/20 0.36
MAP3K11 Q16584 2/20 0.36
JAK3 P52333 2/20 0.34
PRKCA P17252 2/20 0.34
PRKD3 O94806 1/20 0.34
PRKCG P05129 1/20 0.34
PRKCB P05771 1/20 0.34
GLI1 P08151 1/20 0.34
GLI2 P10070 1/20 0.34
CDK4 P11802 1/20 0.34
CTRB1 P17538 1/20 0.34
PRKACA P17612 1/20 0.34
PRKACG P22612 1/20 0.34
PRKACB P22694 1/20 0.34
CCND1 P24385 1/20 0.34
PRKCH P24723 1/20 0.34
PRKCI P41743 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31303417 0.78 PIM1 (0.44) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL18863294 0.78 ADORA2A (0.41) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL23089702 0.78 PIM1 (0.44) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL3039244 0.78 PARP1 (0.36) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL3046642 0.78 MAP3K9 (0.36) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL3040957 0.78 ROCK2 (0.37) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL3039550 0.76 CLK1 (0.43) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL3046629 0.75 MAP3K9 (0.37) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL31158845 0.74 HTR2A (0.40) CLK1CLK2CLK3MAP3K9MAP3K11
SCHEMBL23467712 0.74 CSF1R (0.41) CLK1CLK2CLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024201248-A1 COMPOUNDS AND METHODS FOR DEGRADING GSPT1 PIN THERAPEUTICS, INC. (KR) 2024-10-03 WO disclosed
US-7745641-B2 Nitrogen-containing heterocyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-29 US disclosed
EP-2108642-A1 JAK INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2009-10-14 EP disclosed
US-20090054407-A1 Nitrogen-containing heterocyclic compound KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1880993-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054407-A1 Nitrogen-containing heterocyclic compound NR4A1, NR5A2, PRMT8 CLK1 3126/4885CLK2 2689/4885CLK3 1731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.